Related Experiment Videos
PHarmacist Avoidance or Reductions in Medical Costs in PALLiative Care Inpatient Services: PHARM-PALL
1Department of Pharmacy, Providence St. Peter Hospital, Olympia, Washington, USA.
Journal of Palliative Medicine
|August 6, 2026
Summary
An inpatient palliative care (PC) pharmacist generated over $1.3 million in cost avoidance through clinical interventions. This demonstrates significant financial benefits from PC pharmacist services, impacting healthcare spending.
Area of Science:
- Pharmacoeconomics
- Palliative Care
- Health Services Research
Background:
- Inpatient palliative care (PC) pharmacists improve clinical and team outcomes.
- Financial outcome data for PC pharmacists remain limited.
Purpose of the Study:
- Quantify cost avoidance (CA) from a full-time inpatient PC pharmacist.
- Assess financial impact based on clinical interventions.
Main Methods:
- Retrospective review of PC pharmacist interventions.
- Data collected from two community hospitals (January-June 2024).
Main Results:
- 1015 interventions performed, 698 accepted.
- Total CA: $1,336,717; Annualized CA: $2.68 million.
- High CA-to-salary ratio (21:1).
Conclusions:
- PC pharmacists significantly reduce healthcare costs.
- Key areas include deprescribing and identifying untreated indications.
- PC pharmacist expertise drives therapeutic recommendations and cost savings.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...